Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (Nasdaq: COO) is a global medical device company with two main business units, CooperVision and CooperSurgical, and its news flow reflects this mix of vision care and women’s health activities. Company press releases regularly provide updates on quarterly and annual financial results, including revenue, earnings per share, margins, and free cash flow, along with commentary from management on operational performance and priorities.
Investors following COO news will see detailed segment information for CooperVision and CooperSurgical, such as revenue by product category and geography, as well as explanations of non‑GAAP metrics, constant currency growth, and organic growth. Releases also describe reorganization and integration efforts, business optimization charges, and product line exits, offering context on how these actions affect reported margins and future cost structure.
CooperCompanies’ news also covers corporate governance and strategic topics. Recent announcements include changes in Board leadership, the appointment of new independent directors, and a formal strategic review of the company’s businesses, corporate structure, and capital allocation priorities. The company has disclosed cooperation agreements with investment partners and expansions of its share repurchase program, including a Board‑approved increase that brought total authorization to $2 billion.
In addition, CooperCompanies issues notices about upcoming earnings releases, conference calls, and participation in healthcare investment conferences, where senior executives present and answer questions. For those interested in the broader eye care landscape, external communications related to CooperVision highlight its role in contact lenses and myopia management. This news page brings together these financial, strategic, and industry‑related updates in one place for users tracking COO.
CooperCompanies (Nasdaq: COO) has announced the acquisition of obp Surgical, a U.S.-based medical device company, for approximately $100 million. This strategic move expands CooperSurgical's portfolio with obp's suite of single-use cordless surgical retractors and suction devices, which generated around $14.5 million in trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper's non-GAAP earnings per share in fiscal 2024 and accretive thereafter.
The integration of obp Surgical's ONETRAC™ portfolio complements CooperSurgical's existing surgical products, including INSORB®, Lone Star®, and the Doppler Blood Flow Monitor. This acquisition aligns with CooperCompanies' commitment to providing clinicians with a broader range of innovative surgical technologies and is set to be reported as part of its Office and Surgical category within the CooperSurgical business starting in fiscal Q4 2024.
Evolus (NASDAQ: EOLS), a performance beauty company, has appointed Albert G. White III to its Board of Directors, effective July 1. White is currently the President and CEO of The Cooper Companies and will also join Evolus' Compensation Committee.
Chairman Vik Malik emphasized White's extensive industry experience and leadership, noting that his expertise will support Evolus' transition from a single-product company to a multi-product beauty innovator. White expressed enthusiasm for joining Evolus at a pivotal time, highlighting the success of the company's flagship product, Jeuveau, and its promising pipeline of filler products.
White's extensive background includes roles as CEO, CFO, and Chief Strategy Officer at Cooper Companies, as well as positions in investor relations and treasury. Evolus' Board will now consist of seven directors, six of whom are independent.
CooperCompanies (Nasdaq: COO) announced its Q2 2024 financial results, showing a 7% year-over-year revenue increase to $942.6 million. CooperVision (CVI) revenue rose 8% to $635.9 million, while CooperSurgical (CSI) revenue increased 6% to $306.7 million. GAAP diluted EPS was $0.44, up 122% from last year's Q2. Non-GAAP diluted EPS was $0.85, a 10% increase. Gross margin held steady at 67%. Operating margin improved to 17% from 11% last year. Interest expense rose to $28.9 million due to higher debt and interest rates. Free cash flow was $36.9 million. The company raised its FY 2024 guidance, predicting total revenue of $3.863-$3.905 billion and non-GAAP EPS of $3.54-$3.60.
CooperCompanies released its 2023 Environmental, Social, and Governance (ESG) Report, highlighting their efforts in health, wellness, and environmental protection. The company made healthcare solutions more accessible in underserved communities and invested in global employee development. The report, aligned with the Sustainability Accounting Standards Board (SASB) framework, provides updated and expanded ESG performance data. CEO Al White emphasized the company's commitment to sustainability and innovation.
Find the full report at: https://coopercos.com/esg/
CooperCompanies (Nasdaq: COO), a global leader in medical devices, announced its participation in the Jefferies Global Healthcare Conference on June 6, 2024. Brian Andrews, the Executive Vice President, Chief Financial Officer & Treasurer, will represent the company in a session at 1:30 PM ET. The presentation will be accessible via a webcast on the CooperCompanies' investor relations website.
CooperCompanies (Nasdaq: COO), a global medical device firm, is set to participate in the William Blair Growth Stock Conference on June 5, 2024. Dan McBride, Executive Vice President & Chief Operating Officer, will represent the company in a session at 11:00 AM ET. Interested parties can view the webcast via the CooperCompanies' investor website.
The Canadian Association of Optometrists has launched a digital campaign called 'GetEyeWise' during Vision Health Month to raise awareness about eye health and encourage regular eye exams. The campaign aims to educate Canadians about the importance of eye care, especially early detection of eye-threatening conditions. With the support of various provincial associations of optometrists and industry sponsors, the initiative highlights the urgent need for public education on eye health and vision care.
CooperCompanies will release its second quarter 2024 financial results on May 30, 2024, at 4:15 PM ET. A conference call to discuss the results and corporate developments will follow at 5:00 PM ET. Investors can access the call via dial-in number 800-715-9871 and conference ID 1712676. An audio webcast and replay will be available at http://investor.coopercos.com.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
